Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity

Ruitian Liu, Bin Yuan, Sharareh Emadi, Andleeb Zameer, Philip Schulz, Chad McAllister, Yuri Lyubchenko, Gaddam Goud, Michael R. Sierks

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

β-Amyloid (Aβ) is a major pathological determinant of Alzheimer's disease (AD). Both active and passive immunization studies have shown that antibodies against Aβ are effective in decreasing cerebral Aβ levels, reducing Aβ accumulation, and attenuating cognitive deficits in animal models of AD. However, the therapeutic potential of these antibodies in human AD patients is limited because of adverse inflammatory reactions and cerebral hemorrhaging associated with the treatments. Here we show that single chain variable fragments (scFv's) represent an attractive alternative to more conventional antibody-based therapeutics to reduce Aβ toxicity. The binding affinities and binding epitopes of two different scFv's to Aβ were characterized using a surface plasmon resonance (SPR) biosensor. An scFv binding the 17-28 region of Aβ effectively inhibited in vitro aggregation of Aβ as determined by thioflavin T (ThT) fluorescence staining and atomic force microscopy (AFM) analysis, while an scFv binding the carboxyl-terminal region of Aβ (residues 29-40) did not inhibit aggregation. The scFv to the 17-28 region when co-incubated with Aβ not only decreased aggregation but also eliminated any toxic effects of aggregated Aβ on the human neuroblastoma cell line, SH-SY5Y. The ability of scFv's to inhibit both aggregation and cytotoxicity of Aβ indicates that scFv's have potential therapeutic value for treating AD.

Original languageEnglish (US)
Pages (from-to)6959-6967
Number of pages9
JournalBiochemistry
Volume43
Issue number22
DOIs
StatePublished - Jun 8 2004

Fingerprint

Single-Chain Antibodies
Amyloid
Alzheimer Disease
Agglomeration
Antibodies
Immunization
Aptitude
Passive Immunization
Surface Plasmon Resonance
Atomic Force Microscopy
Poisons
Surface plasmon resonance
Biosensing Techniques
Therapeutics
Cytotoxicity
Neuroblastoma
Biosensors
Toxicity
Epitopes
Atomic force microscopy

ASJC Scopus subject areas

  • Biochemistry

Cite this

Liu, R., Yuan, B., Emadi, S., Zameer, A., Schulz, P., McAllister, C., ... Sierks, M. R. (2004). Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity. Biochemistry, 43(22), 6959-6967. https://doi.org/10.1021/bi049933o

Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity. / Liu, Ruitian; Yuan, Bin; Emadi, Sharareh; Zameer, Andleeb; Schulz, Philip; McAllister, Chad; Lyubchenko, Yuri; Goud, Gaddam; Sierks, Michael R.

In: Biochemistry, Vol. 43, No. 22, 08.06.2004, p. 6959-6967.

Research output: Contribution to journalArticle

Liu, R, Yuan, B, Emadi, S, Zameer, A, Schulz, P, McAllister, C, Lyubchenko, Y, Goud, G & Sierks, MR 2004, 'Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity', Biochemistry, vol. 43, no. 22, pp. 6959-6967. https://doi.org/10.1021/bi049933o
Liu, Ruitian ; Yuan, Bin ; Emadi, Sharareh ; Zameer, Andleeb ; Schulz, Philip ; McAllister, Chad ; Lyubchenko, Yuri ; Goud, Gaddam ; Sierks, Michael R. / Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity. In: Biochemistry. 2004 ; Vol. 43, No. 22. pp. 6959-6967.
@article{f2db68d635c342de81f7ac28b1baa4fc,
title = "Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity",
abstract = "β-Amyloid (Aβ) is a major pathological determinant of Alzheimer's disease (AD). Both active and passive immunization studies have shown that antibodies against Aβ are effective in decreasing cerebral Aβ levels, reducing Aβ accumulation, and attenuating cognitive deficits in animal models of AD. However, the therapeutic potential of these antibodies in human AD patients is limited because of adverse inflammatory reactions and cerebral hemorrhaging associated with the treatments. Here we show that single chain variable fragments (scFv's) represent an attractive alternative to more conventional antibody-based therapeutics to reduce Aβ toxicity. The binding affinities and binding epitopes of two different scFv's to Aβ were characterized using a surface plasmon resonance (SPR) biosensor. An scFv binding the 17-28 region of Aβ effectively inhibited in vitro aggregation of Aβ as determined by thioflavin T (ThT) fluorescence staining and atomic force microscopy (AFM) analysis, while an scFv binding the carboxyl-terminal region of Aβ (residues 29-40) did not inhibit aggregation. The scFv to the 17-28 region when co-incubated with Aβ not only decreased aggregation but also eliminated any toxic effects of aggregated Aβ on the human neuroblastoma cell line, SH-SY5Y. The ability of scFv's to inhibit both aggregation and cytotoxicity of Aβ indicates that scFv's have potential therapeutic value for treating AD.",
author = "Ruitian Liu and Bin Yuan and Sharareh Emadi and Andleeb Zameer and Philip Schulz and Chad McAllister and Yuri Lyubchenko and Gaddam Goud and Sierks, {Michael R.}",
year = "2004",
month = "6",
day = "8",
doi = "10.1021/bi049933o",
language = "English (US)",
volume = "43",
pages = "6959--6967",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity

AU - Liu, Ruitian

AU - Yuan, Bin

AU - Emadi, Sharareh

AU - Zameer, Andleeb

AU - Schulz, Philip

AU - McAllister, Chad

AU - Lyubchenko, Yuri

AU - Goud, Gaddam

AU - Sierks, Michael R.

PY - 2004/6/8

Y1 - 2004/6/8

N2 - β-Amyloid (Aβ) is a major pathological determinant of Alzheimer's disease (AD). Both active and passive immunization studies have shown that antibodies against Aβ are effective in decreasing cerebral Aβ levels, reducing Aβ accumulation, and attenuating cognitive deficits in animal models of AD. However, the therapeutic potential of these antibodies in human AD patients is limited because of adverse inflammatory reactions and cerebral hemorrhaging associated with the treatments. Here we show that single chain variable fragments (scFv's) represent an attractive alternative to more conventional antibody-based therapeutics to reduce Aβ toxicity. The binding affinities and binding epitopes of two different scFv's to Aβ were characterized using a surface plasmon resonance (SPR) biosensor. An scFv binding the 17-28 region of Aβ effectively inhibited in vitro aggregation of Aβ as determined by thioflavin T (ThT) fluorescence staining and atomic force microscopy (AFM) analysis, while an scFv binding the carboxyl-terminal region of Aβ (residues 29-40) did not inhibit aggregation. The scFv to the 17-28 region when co-incubated with Aβ not only decreased aggregation but also eliminated any toxic effects of aggregated Aβ on the human neuroblastoma cell line, SH-SY5Y. The ability of scFv's to inhibit both aggregation and cytotoxicity of Aβ indicates that scFv's have potential therapeutic value for treating AD.

AB - β-Amyloid (Aβ) is a major pathological determinant of Alzheimer's disease (AD). Both active and passive immunization studies have shown that antibodies against Aβ are effective in decreasing cerebral Aβ levels, reducing Aβ accumulation, and attenuating cognitive deficits in animal models of AD. However, the therapeutic potential of these antibodies in human AD patients is limited because of adverse inflammatory reactions and cerebral hemorrhaging associated with the treatments. Here we show that single chain variable fragments (scFv's) represent an attractive alternative to more conventional antibody-based therapeutics to reduce Aβ toxicity. The binding affinities and binding epitopes of two different scFv's to Aβ were characterized using a surface plasmon resonance (SPR) biosensor. An scFv binding the 17-28 region of Aβ effectively inhibited in vitro aggregation of Aβ as determined by thioflavin T (ThT) fluorescence staining and atomic force microscopy (AFM) analysis, while an scFv binding the carboxyl-terminal region of Aβ (residues 29-40) did not inhibit aggregation. The scFv to the 17-28 region when co-incubated with Aβ not only decreased aggregation but also eliminated any toxic effects of aggregated Aβ on the human neuroblastoma cell line, SH-SY5Y. The ability of scFv's to inhibit both aggregation and cytotoxicity of Aβ indicates that scFv's have potential therapeutic value for treating AD.

UR - http://www.scopus.com/inward/record.url?scp=2642578354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642578354&partnerID=8YFLogxK

U2 - 10.1021/bi049933o

DO - 10.1021/bi049933o

M3 - Article

C2 - 15170333

AN - SCOPUS:2642578354

VL - 43

SP - 6959

EP - 6967

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 22

ER -